logo
Plus   Neg
Share
Email

GlaxoSmithKline Sells Two Travel Vaccines Rabipur And Encepur To Bavarian Nordic

GlaxoSmithKline plc (GSK,GSK.L) announced the sale of travel vaccines Rabipur for the prevention of rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic. These brands were acquired from Novartis (NVS) in 2015 as part of the acquisition of its vaccines business.

GSK will receive an upfront payment of approximately EUR 301 million or £259 million and milestone payments for a total consideration of up to EUR 955 million or £822 million. The transaction is expected to close by the end of 2019.

GSK noted that both vaccines will continue to be manufactured primarily at Marburg site in Germany until full production is transferred to Bavarian Nordic. The staged technology transfer is expected to commence in the first quarter of 2020 with completion anticipated within 5 years.

Roger Connor, President, Global Vaccines at GSK, said, "This agreement with Bavarian Nordic will enable us to commit greater resources to our key growth assets and to our R&D pipeline, while also ensuring the continued supply of these important and successful vaccines."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Trade Commission (FTC) is in the process of sending out refund checks to consumers who were allegedly misled by Office Depot, Inc. and its software provider Support.com, Inc., into buying computer repair products and services. Out of $34 million, being the total amount of checks, Office Depot paid $25 million and Support.com paid $10 million as part of 2019 settlement. Gap Inc. partnered with fashion resale platform thredUP to facilitate the exchange of secondhand cloths. The retailer in a blog post said its customers can bring secondhand clothes in exchange for shopping credit that can be redeemed at Gap, Banana Republic, Athleta, or Janie and Jack. Customers who redeem their credits at Gap brands will receive an additional 15 percent payout bonus. Coca-Cola Co. (KO) on Friday reaffirmed its guidance for the full-year 2020 and provided an update on the expected impact from COVID-19 on first quarter 2020 results, ahead of its presentation at the Consumer Analyst Group of New York (CAGNY) Conference. For fiscal 2020, the company continues to project...
Follow RTT
>